ValuEngine upgraded shares of TrovaGene (NASDAQ:TROV) from a strong sell rating to a sell rating in a research report report published on Friday, February 2nd.
Several other research firms have also recently commented on TROV. Maxim Group lowered shares of TrovaGene from a buy rating to a hold rating in a research note on Friday, November 10th. lowered shares of TrovaGene from a buy rating to a hold rating in a research note on Wednesday, November 15th. Finally, HC Wainwright initiated coverage on shares of TrovaGene in a research note on Thursday, December 21st. They issued a buy rating and a $1.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. TrovaGene presently has a consensus rating of Hold and a consensus price target of $3.70.
Shares of TrovaGene (NASDAQ TROV) opened at $0.33 on Friday. The stock has a market cap of $17.46, a price-to-earnings ratio of -0.34 and a beta of 0.26. TrovaGene has a 12 month low of $0.23 and a 12 month high of $2.14.
COPYRIGHT VIOLATION NOTICE: “TrovaGene (TROV) Lifted to “Sell” at ValuEngine” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/02/19/valuengine-upgrades-trovagene-trov-to-sell.html.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.